- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947511
Oral-Challenge Study: Steady-State High-ORP Water/Gel Relieves AITC- and Capsaicin-Induced Oral Pain in Healthy Volunteers
Evaluation of Steady-State High-Oxidation-Reduction-Potential Water and Gel for Relief of Oral Pain, Burning and Choking Sensation Provoked by AITC (Wasabi/Horseradish) and Capsaicin (Chili) Among Healthy Human Volunteers
To evaluate the efficacy and safety of stabilized 780±21 mV high-oxidation-potential water to rapidly relieve oral mucosal pain and irritation induced by AITC (wasabi-horseradish) and capsaicin (chili-oil), which activate TRPA1 and TRPV1 sensory ion-channels. Healthy volunteers receive oral 40 mL stabilized high-oxidation-potential water after oral irritant challenge. Pain-irritation NRS scores are assessed at baseline, 3 seconds, 30 seconds, 60 seconds, 120 seconds post-treatment. Safety observations are recorded throughout the study.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is prospective, single-arm, open-label exploratory pilot study in healthy adult volunteers. Two separate oral irritant challenge models are applied: AITC-containing horseradish-wasabi challenge for TRPA1-mediated oral irritation-pain; capsaicin-containing chili-oil challenge for TRPV1-mediated burning oral pain. Total target enrollment is 24 healthy subjects (12 male,12 female). After irritant exposure, subjects take 40 mL stabilized 780±21 mV high-oxidation-potential water, hold in mouth then swallow. Subject-reported 0-10 NRS pain-irritation scores are collected at pre-challenge baseline; post-irritant baseline; 3 s,30 s,60 s,120 s after study product administration. Local oral-mucosal adverse reactions and systemic tolerability are monitored. Pre-existing rabbit ocular-surface safety testing supports mucosal safety of this formulation. This trial focuses on acute seconds-range symptom relief in experimental irritant-pain models.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mizhou Hui
- Phone Number: 13484005199
- Email: mizhou.hui@alumni.utoronto.ca
Study Locations
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- Hynaut Laboratory
-
Contact:
- Xiaoxiao Jia
- Phone Number: 15621486915
- Email: 15621486915@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult volunteers aged 18-60 years old, male and female.
- Body weight range 40 kg-72 kg.
- No active oral-pharyngeal disease, no oral ulcer, gingivitis, pharyngitis at screening.
- Able to understand trial procedure, independently complete NRS numeric rating scale assessments.
- Voluntarily provide written informed consent.
Exclusion Criteria:
- Active oral ulcer, stomatitis, gingival-periodontal acute disease, active pharyngitis.
- Known hypersensitivity to electrolyzed saline / study formulation components.
- Gastro-esophageal reflux disease, active gastrointestinal disorder.
- Pregnant or lactating women.
- Recent consumption (<72 hours) of large-dose spicy / irritant food interfering with pain perception.
- Concurrent participation in other oral-pain or mucosal-related clinical research.
- Psychiatric condition impairing study compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Stabilized High-Oxidation-Potential Oral Water
|
Intervention description: Stabilized electrolyzed saline water with oxidation-potential 780±21 mV. After oral irritant challenge (AITC-horseradish-wasabi or capsaicin-chili-oil), subject takes 40 mL of study liquid, holds in oral cavity briefly then swallow, single administration for each challenge test. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AITC-Induced Oral Pain-Irritation NRS Score
Time Frame: Post-irritant baseline, 3 seconds, 30 seconds post-product administration.
|
Participant self-reported 0-10 numerical rating scale for oral pain, stinging, choking-irritation triggered by AITC-containing horseradish-wasabi; 0 = no pain/irritation, 10 = worst imaginable oral irritation-pain. |
Post-irritant baseline, 3 seconds, 30 seconds post-product administration.
|
|
Capsaicin-Induced Oral Burning-Pain NRS Score
Time Frame: Post-irritant baseline, 3 seconds, 30 seconds, 60 seconds,120 seconds post-product administration.
|
Participant self-reported 0-10 NRS for burning-pain triggered by capsaicin-containing chili-oil; 0 = no burning-pain,10 = worst imaginable burning-pain. |
Post-irritant baseline, 3 seconds, 30 seconds, 60 seconds,120 seconds post-product administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant Overall Subjective Relief Assessment Score
Time Frame: 120 seconds after product administration for each irritant challenge.
|
Subject-rated 0-10 scale for overall subjective relief of oral discomfort after each challenge test;0=no relief,10=complete relief. |
120 seconds after product administration for each irritant challenge.
|
|
Incidence of Adverse Events
Time Frame: Throughout entire study visit period (within 30 minutes of product exposure).
|
Incidence of product-related adverse events including oral mucosal stinging, numbness, gastrointestinal upset, throat irritation, nausea. |
Throughout entire study visit period (within 30 minutes of product exposure).
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HO-ORP-2026-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.